Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income: 2021-2024

Historic Equity Income for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Dec 2024 value amounting to -$573,000.

  • Amphastar Pharmaceuticals' Equity Income rose 27.01% to -$573,000 in Q1 2024 from the same period last year, while for Mar 2024 it was -$1.8 million, marking a year-over-year decrease of 40.51%. This contributed to the annual value of -$573,000 for FY2024, which is 71.08% up from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Equity Income is -$573,000, which was up 71.08% from -$2.0 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Equity Income peaked at -$208,000 during FY2021, and registered a low of -$2.0 million during FY2023.
  • In the last 3 years, Amphastar Pharmaceuticals' Equity Income had a median value of -$1.2 million in 2022 and averaged -$1.2 million.
  • Its Equity Income has fluctuated over the past 5 years, first plummeted by 465.87% in 2022, then spiked by 71.08% in 2024.
  • Yearly analysis of 4 years shows Amphastar Pharmaceuticals' Equity Income stood at -$208,000 in 2021, then tumbled by 465.87% to -$1.2 million in 2022, then plummeted by 68.31% to -$2.0 million in 2023, then surged by 71.08% to -$573,000 in 2024.